A novel mucopolysaccharidosis type I associated splice site mutation and IDUA splice variants

详细信息    查看全文

• 作者：Sara  ; Bremer^a ;   ; ^{sara.bremer@oslo-universitetssykehus.no} ; Annika  ; Ohlsson^b ; Else  ; Brodtkorb^c ; Helge  ; Rootwelt^a ; Terje  ; Rootwelt^d ; Berit  ; Woldseth^a ; Lars  ; Mø ; rkrid^a
• 关键词：Iduronidase (IDUA) ; Mucopolysaccharidosis I ; Mutation ; RNA splicing
• 刊名：Molecular Genetics and Metabolism
• 出版年：2011
• 出版时间：November 2011
• 年：2011
• 卷：104
• 期：3
• 页码：289-294
• 全文大小：340 K

文摘

Mucopolysaccharidosis type I is an autosomal recessive disorder caused by deficiency of ¦Á-l-iduronidase, encoded by the IDUA gene. More than 100 disease causing mutations have been reported in the gene, resulting in a wide range of phenotypes. Here we describe a previously unreported IDUA splice site mutation (:g.21632G>C; :c.1727+3G>C) causing a Hurler phenotype in a patient heterozygous for the common p.Q70X (:g.5862C>T) mutation. Sequence analysis of IDUA transcripts demonstrated that the g.21632G>C mutation results in aberrant splicing of intron 12 (:c.1727_1728insGTCC), introducing a frame shift and premature termination codon (:p.Cys577SerfsX15). Gene expression studies suggest that the deleterious effect of the mutation is primarily due to a C-terminal truncation of the encoded polypeptide. Furthermore, we observed that both normal and mutant IDUA alleles give rise to alternatively spliced transcripts in leukocytes. Exclusion of exon 4 appeared to be the predominant alternative splicing event, probably resulting in polypeptides lacking iduronidase activity. The Hurler patient demonstrated exon 4 skipping in 5.6 % of IDUA transcripts, while exon 4 skipping ranged 25?4 % of transcripts among healthy individuals (n = 5). Alternative splicing might represent a mechanism for regulation of this enzyme, and the lower level of exon 4 skipping in the patient might be a response to intracellular accumulation of iduronidase substrates. Molecular characterization of IDUA mutations and splicing may assist early prediction of mucopolysaccharidosis type I phenotypes and increase the understanding of disease mechanisms. This is important considering the choice of current treatment options and for the development of future therapies.